These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27817208)

  • 41. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Bailey TS; Takács R; Tinahones FJ; Rao PV; Tsoukas GM; Thomsen AB; Kaltoft MS; Maislos M
    Diabetes Obes Metab; 2016 Dec; 18(12):1191-1198. PubMed ID: 27381275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
    O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
    Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
    Rosenstock J; Sorli CH; Trautmann ME; Morales C; Wendisch U; Dailey G; Hompesch M; Choi IY; Kang J; Stewart J; Yoon KH
    Diabetes Care; 2019 Sep; 42(9):1733-1741. PubMed ID: 31320446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
    Shomali ME; Ørsted DD; Cannon AJ
    Diabet Med; 2017 Feb; 34(2):197-203. PubMed ID: 27412701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
    Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
    Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
    Komatsu M; Watada H; Kaneko S; Ross Agner BF; Nishida T; Kaku K
    J Diabetes Investig; 2021 Sep; 12(9):1610-1618. PubMed ID: 33595901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
    Bode BW; Brett J; Falahati A; Pratley RE
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
    Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
    Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
    Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.
    Khera R; Pandey A; Chandar AK; Murad MH; Prokop LJ; Neeland IJ; Berry JD; Camilleri M; Singh S
    Gastroenterology; 2018 Apr; 154(5):1309-1319.e7. PubMed ID: 29305933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
    Sprung VS; Kemp GJ; Wilding JP; Adams V; Murphy K; Burgess M; Emegbo S; Thomas M; Needham AJ; Weimken A; Schwab RJ; Manuel A; Craig SE; Cuthbertson DJ
    BMJ Open; 2020 Jul; 10(7):e038856. PubMed ID: 32699168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.
    Kim SH; Abbasi F; Lamendola C; Liu A; Ariel D; Schaaf P; Grove K; Tomasso V; Ochoa H; Liu YV; Chen YD; Reaven G
    Diabetes Care; 2013 Oct; 36(10):3276-82. PubMed ID: 23835684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial.
    Halperin F; Ding SA; Simonson DC; Panosian J; Goebel-Fabbri A; Wewalka M; Hamdy O; Abrahamson M; Clancy K; Foster K; Lautz D; Vernon A; Goldfine AB
    JAMA Surg; 2014 Jul; 149(7):716-26. PubMed ID: 24899464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Liraglutide on Arterial Inflammation Assessed as [
    Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
    Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.